\nTime Frame<\/td>\n | 2 year endpoint<\/td>\n | Time Frame<\/td>\n | baseline, 6, 12, 18, 24 months post randomization<\/td>\n | Time Frame<\/td>\n | 2 year endpoint<\/td>\n | Time Frame<\/td>\n | baseline, 6, 12, 18, 24 months post randomization<\/td>\n | Time Frame<\/td>\n | baseline, 6, 12, 18, 24 months post randomization<\/td>\n | Time Frame<\/td>\n | baseline, 6, 12, 18, 24 months post randomization<\/td>\n | Time Frame<\/td>\n | baseline, 6, 12, 18, 24 months post randomization<\/td>\n<\/tr>\n |
\nDescription<\/td>\n | Progression of echocardiographic features of latent RHD to borderline to definite, or definite to mild or definite to moderate\/severe<\/td>\n | Description<\/td>\n | The aim is to understand the costs and effectiveness of the intervention. Costs will include intervention and disease specific costs, capturing both health system and family out of pocket costs. Participants will complete a questionnaire asking about out-of-pocket cost (medications, supplies, consultation fees) and lost productivity (including missed school and workdays) due to the intervention. Costs will be measured in the local currency (Uganda Shillings) and presented in United States dollars (USD)<\/td>\n | Description<\/td>\n | In order to understand health center and community costs, 10 randomly selected health care facilities (including level II, III, and IV facilities) will be surveyed to obtain direct costs of medications, supplies as well as any administration and professional fees associated with outpatient and inpatient visits.<\/td>\n | Description<\/td>\n | Treatment acceptance will be assessed with the widely-used Chronic Treatment Acceptance (ACCEPT) questionnaire, a generic medication acceptance instrument validated for chronic conditions. This 25-item survey consists of six areas of focus: medication convenience (3 items), length of treatment (2 items), medication constraints (9 items), medication side effects (5 items), medication effectiveness (3 items), medication advantages (3 items). Responses are rated on a 5-point Likert scale and scores of 1 through 4 indicating increasing levels of acceptance.<\/td>\n | Description<\/td>\n | Treatment Satisfaction will be assessed with the 14-item Abbreviated Treatment Satisfaction Questionnaire (v 1.4). This widely used survey contains 4 areas of focus including satisfaction of treatment effectiveness (3 items), satisfaction with treatment side effects (5 items), satisfaction with treatment convenience (3 items), and a global treatment satisfaction (3 items). Scores are then transformed to a score of 0-100 to create the overall scale score and the subcategory scores, with higher scores representing higher treatment satisfaction on that domain.<\/td>\n | Description<\/td>\n | Health Related Quality of Life will be measured using the Pediatric Quality of Life Inventory Version 4.0 Generic Core (PedsQL 4.0) questionnaire. The PedsQLTM4.0 is a 23-item survey for children aged 5-18 which assesses HRQOL. It has four areas of focus: Physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), school functioning (5 items). Each item has five possible responses measuring the extent to which the item was a problem during the past month. The possible responses are measured using a 5-point Likert scale from 0=never a problem to 4 = almost always a problem. These reverse scaled scores are then transformed to a score of 0-100 to create the overall scaled score and the subcategory scores, with higher scores representing better quality of life.<\/td>\n | Description<\/td>\n | Interviews will be used to collect qualitative data around participants perceptions of the impact of RHD and its treatment on their activities of daily living and quality of life including experiences with IM or oral penicillin prophylaxis.<\/td>\n<\/tr>\n<\/table><\/div>\n |